Lung Sarcoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Sarcoma

MalaCards integrated aliases for Lung Sarcoma:

Name: Lung Sarcoma 12 14 69
Pulmonary Sarcoma 12


External Ids:

Disease Ontology 12 DOID:2784
NCIt 47 C4860
UMLS 69 C0598790

Summaries for Lung Sarcoma

Disease Ontology : 12 A lung cancer that is located in the lung and that arises from transformed cells of mesenchymal origin.

MalaCards based summary : Lung Sarcoma, also known as pulmonary sarcoma, is related to malignant neoplasm of acoustic nerve and parkinsonism with dementia of guadeloupe. An important gene associated with Lung Sarcoma is SKI (SKI Proto-Oncogene), and among its related pathways/superpathways are Corticotropin-releasing hormone signaling pathway and Glucocorticoid receptor regulatory network. The drugs Busulfan and Dactinomycin have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and liver, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and digestive/alimentary

Related Diseases for Lung Sarcoma

Graphical network of the top 20 diseases related to Lung Sarcoma:

Diseases related to Lung Sarcoma

Symptoms & Phenotypes for Lung Sarcoma

GenomeRNAi Phenotypes related to Lung Sarcoma according to GeneCards Suite gene sharing:

id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.44 SSX2B
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.44 SKI
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.44 SSX2B
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.44 EWSR1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.44 NME1-NME2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.44 EWSR1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.44 EWSR1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.44 EWSR1 NME1-NME2 SKI SSX2B
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.44 EWSR1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.44 EWSR1

MGI Mouse Phenotypes related to Lung Sarcoma:

id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 IL18 IL2 KRT5 LYZ NF1 PLAT
2 respiratory system MP:0005388 9.17 SFTPA1 THBD CREB1 IL2 LYZ NF1

Drugs & Therapeutics for Lung Sarcoma

Drugs for Lung Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
Dactinomycin Approved Phase 3 50-76-0 2019 457193
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
Zoledronic acid Approved Phase 3 118072-93-8 68740
Melatonin Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 73-31-4 896
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
19 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
Treosulfan Investigational Phase 3 299-75-2 9296
21 Alkylating Agents Phase 3,Phase 1,Phase 2
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Anti-Infective Agents Phase 3,Phase 2,Phase 1
25 Antimitotic Agents Phase 3,Phase 2,Phase 1
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
27 Etoposide phosphate Phase 3,Phase 2,Phase 1
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
29 Isophosphamide mustard Phase 3,Phase 2,Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
31 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2
32 Analgesics Phase 3,Phase 2,Phase 1
33 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
34 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
35 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2,Phase 1
36 Antirheumatic Agents Phase 3,Phase 2,Phase 1
37 Cyclooxygenase 2 Inhibitors Phase 3,Phase 2,Phase 1
38 Cyclooxygenase Inhibitors Phase 3,Phase 2,Phase 1
39 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
40 Liver Extracts Phase 3,Phase 1,Phase 2
41 Antibodies Phase 3,Phase 1,Phase 2
42 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
43 Immunoglobulins Phase 3,Phase 1,Phase 2
44 Antimetabolites Phase 3,Phase 2,Phase 1
45 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
46 Antiviral Agents Phase 3,Phase 2,Phase 1
47 Antioxidants Phase 2, Phase 3
48 Central Nervous System Depressants Phase 2, Phase 3, Phase 1
49 Protective Agents Phase 2, Phase 3,Phase 1
50 Adjuvants, Anesthesia Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 204)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
2 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Completed NCT00243685 Phase 2, Phase 3
5 Melatonin In Reduction of Chemotherapy-Induced Toxicity (MIRCIT) Trial Completed NCT01706627 Phase 2, Phase 3 10 mg Melatonin;20 mg Melatonin;Matched placebo
6 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Study in Localized and Disseminated Ewing Sarcoma Recruiting NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
9 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Vincristine Sulfate
10 Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC Active, not recruiting NCT01933932 Phase 3 Selumetinib;Docetaxel;Placebo;Pegylated G-CSF
11 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
12 Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer Terminated NCT01259284 Phase 2, Phase 3 Atorvastatin
13 Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3 Enbrel
14 Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma Unknown status NCT01812018 Phase 2 Endostar;Gemcitabine;Docetaxel
15 Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unknown status NCT00906061 Phase 2 Gemcitabine and Docetaxel
16 Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients Unknown status NCT01134250 Phase 1, Phase 2 F16IL2 in combination with paclitaxel
17 FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer Unknown status NCT01503372 Phase 2 Pazopanib;5-FU, Oxaliplatin, Leukovorin (FLO)
18 Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer Unknown status NCT00622466 Phase 2 paclitaxel;sorafenib tosylate
19 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
20 Aerosol L9-NC and Temozolomide in Ewing's Sarcoma Completed NCT00492141 Phase 1, Phase 2 Temozolomide;L9-NC
21 Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery Completed NCT00652860 Phase 2 cisplatin;doxorubicin hydrochloride;ifosfamide;mitomycin C
22 Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma Completed NCT00066365 Phase 2
23 A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer Completed NCT02283320 Phase 2 BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
24 A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. Completed NCT01124864 Phase 2 AUY922
25 Alanosine in Treating Patients With Cancer Completed NCT00062283 Phase 2 L-alanosine
26 Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... Completed NCT01229150 Phase 2 AZD6244;Erlotinib;AZD6244 + Erlotinib
27 Maximum Tolerated Dose Study of Belinostat (PXD-101)in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01310244 Phase 1, Phase 2 Belinostat, Carboplatin, Paclitaxel
28 Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types Completed NCT00633789 Phase 2 brivanib;Placebo
29 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
30 A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors Completed NCT00841191 Phase 1, Phase 2 CNTO 328; Anti-interleukin-6 monoclonal antibody;CNTO 328; Anti-interleukin-6 monoclonal antibody;CNTO 328; Anti-interleukin-6 monoclonal antibody;CNTO 328; Anti-interleukin-6 monoclonal antibody;CNTO 328; Anti-interleukin-6 monoclonal antibody;CNTO 328; Anti-interleukin-6 monoclonal antibody;CNTO 328; Anti-interleukin-6 monoclonal antibody
31 A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone Completed NCT00265317 Phase 2 erlotinib;sunitinib;erlotinib;placebo
32 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
33 Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver Completed NCT00041808 Phase 1, Phase 2 MTC-DOX for Injection
34 Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung Completed NCT00102531 Phase 1, Phase 2 Cisplatin liposomal
35 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Completed NCT00587964 Phase 2
36 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
37 Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Completed NCT00030667 Phase 2 imatinib mesylate
38 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Completed NCT00309907 Phase 2 methylprednisolone
39 A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen Completed NCT00769067 Phase 2 Erlotinib;PF-00299804
40 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
41 Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases Recruiting NCT02181829 Phase 2
42 Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors Recruiting NCT02581384 Phase 1, Phase 2
43 Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Recruiting NCT02859415 Phase 1, Phase 2 Mithramycin
44 First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years Recruiting NCT03011528 Phase 2 VDC-IE x2;VDC-IE;TEMIRI;Consolidation BuMel;Maintenance
45 Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Recruiting NCT02275286 Phase 1, Phase 2 Trabectedin
46 Stereotactic Radiation Therapy for Pediatric Sarcomas Recruiting NCT01763970 Phase 2
47 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
48 Study of Abemaciclib in Dedifferentiated Liposarcoma Recruiting NCT02846987 Phase 2 Abemaciclib
49 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Recruiting NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
50 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting NCT02568267 Phase 2 Entrectinib

Search NIH Clinical Center for Lung Sarcoma

Genetic Tests for Lung Sarcoma

Anatomical Context for Lung Sarcoma

MalaCards organs/tissues related to Lung Sarcoma:

Lung, Breast, Liver, Bone, T Cells, Testes, Brain

Publications for Lung Sarcoma

Articles related to Lung Sarcoma:

(show all 14)
id Title Authors Year
Primary lung sarcoma treated with stereotactic ablative radiotherapy: a case report. ( 28740403 )
Effect of Shenfu injection on immune function of mice bearing Lewis lung sarcoma with chemotherapy. ( 26831661 )
High-grade primary myxoid lung sarcoma presenting as recurrent hemorrhagic pleural effusions in a young woman. ( 27489706 )
An example of difficulty in diagnosising and treating lung sarcoma. ( 25900706 )
Bilateral anterior sternothoracotomy (clamshell incision): a suitable alternative for bilateral lung sarcoma metastasis in children. ( 25064077 )
Pulmonary sequestration presented as massive left hemothorax and associated with primary lung sarcoma. ( 24267748 )
Primary lung sarcoma. ( 19892455 )
Intense paraneoplastic neutrophilic leukemoid reaction related to a G-CSF-secreting lung sarcoma. ( 16247754 )
Technique and results of hyperthermic (41 degrees C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis. ( 12103371 )
Establishment of a new lung sarcoma cell line from a human lung carcinosarcoma. ( 8050085 )
Simultaneous primary lung sarcoma and carcinoma. ( 1556872 )
Blocking of lectin-like adhesion molecules on pulmonary cells inhibits lung sarcoma L-1 colonization in BALB/c-mice. ( 2737266 )
Long-term development of a primary lung sarcoma, probably lymphangiosarcoma--a case report. ( 6206599 )
Lung sarcoma. ( 21022634 )

Variations for Lung Sarcoma

Expression for Lung Sarcoma

Search GEO for disease gene expression data for Lung Sarcoma.

Pathways for Lung Sarcoma

GO Terms for Lung Sarcoma

Cellular components related to Lung Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 HIST2H2BE IFNA1 IL18 IL2 LYZ PLAT
2 lamellar body GO:0042599 8.96 SFTPA1 SFTPA2

Biological processes related to Lung Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular response to fatty acid GO:0071398 9.5 CREB1 NME1 NME2
2 myelination in peripheral nervous system GO:0022011 9.46 NF1 SKI
3 positive regulation of interleukin-17 production GO:0032740 9.43 IL18 IL2
4 nucleoside diphosphate phosphorylation GO:0006165 9.43 NME1 NME1-NME2 NME2
5 positive regulation of tissue remodeling GO:0034105 9.4 IL18 IL2
6 negative regulation of myeloid leukocyte differentiation GO:0002762 9.37 NME1 NME2
7 CTP biosynthetic process GO:0006241 9.33 NME1 NME1-NME2 NME2
8 GTP biosynthetic process GO:0006183 9.13 NME1 NME1-NME2 NME2
9 UTP biosynthetic process GO:0006228 8.8 NME1 NME1-NME2 NME2

Molecular functions related to Lung Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament binding GO:0019215 8.96 NME1 NME2
2 nucleoside diphosphate kinase activity GO:0004550 8.8 NME1 NME1-NME2 NME2

Sources for Lung Sarcoma

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....